John Byrd is a Distinguished University Professor at The Ohio State University, Columbus, OH, Co-Leader of the Leukemia Research Program, and Senior Advisor of Experimental Therapeutics at the The James Cancer Hospital and Solove Research Institute in Columbus, OH. Prof. Byrd also holds the D. Warren Brown Designated Chair in Leukemia Research, and is the Chief Medical Officer for Beat AML, a division of the Leukemia and Lymphoma Society.
Prof. Byrd received his medical degree from the University of Arkansas College of Medicine, Little Rock, AR, and subsequently completed his residency and a fellowship in medical oncology at the Walter Reed Army Medical Center, Washington, DC, as well as a further fellowship in medical oncology at the Johns Hopkins Medical Center, Baltimore, MD. He is also a member of the National Cancer Institute’s Leukemia Steering Committee and the American Society of Clinical Investigation, and Chair of the Leukemia and Correlative Science Committee within the Alliance for Clinical Trials in Oncology.
Speaking on lymphoma, leukemia, neoplasms
Prof. Byrd’s research primarily involves treating patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), with a particular focus on translational immune and molecular pharmacology. He has also focused on translational and clinical drug development and his effort has resulted in 4 CLL drugs (rituximab, idelalisib, ibrutinib and acalabrutinib) getting FDA approval.
In addition, Prof. Byrd has recently been involved in a Phase I trials assessing the safety and activity of selinexor in combination with decitabine in patients with AML.